Biotech News
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
investors.urogen.com2026-05-06 15:01 EST
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt facility and provide additional non-dilutive capital Additional $50 million tranche